CTOs on the Move

Protea Biosciences

www.proteabio.com

 
Protea Biosciences is a Morgantown, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.proteabio.com
  • 955 Hartman Run Rd Ste 210
    Morgantown, WV USA 26505
  • Phone: 304.292.2226

Executives

Name Title Contact Details

Similar Companies

Locus Fermentation Solutions

Locus Fermentation Solutions is the the accelerator company for Locus Agricultural Solutions and Locus Bio-Energy Solutions, LLC.

Kiadis

Kiadis Pharma is a clinical stage biopharmaceutical company focused on developing innovative and potentially life-saving therapies for blood cancer patients where pharmacological standard of care is no longer an alternative. The Company`s main focus is on the development of a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients, thus making them safe and available as the last potentially life saving option. Stem cell transplantation is currently the only potentially curative treatment available for late stage blood cancer patients; however, a standard of care matching donor is only available for half of patients who are progressing with radiation therapy and chemotherapy.

Apic Bio

Apic Bio is committed to finding cures for patients with genetic diseases.

Triad Life Sciences

Triad Life Sciences completes A$25m funding round, anticipates ASX listing in coming months – Learn More >> Triad Life Sciences® introduces InnovaMatrix™Technology Platform, a next-generation extracellular matrix (ECM) product that advance...

Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.